atidarsagene autotemcel
| Brand name | Lenmeldy |
|---|---|
| Active ingredient | atidarsagene autotemcel |
| Strength | 2 x 10^6 to 11.8 x 10^6CELL/ML |
| Dosage form | Suspension |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | March 2024 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.